Influenza vaccine - Jiangsu Jindike Biotechnology

Drug Profile

Influenza vaccine - Jiangsu Jindike Biotechnology

Latest Information Update: 22 Sep 2016

Price : $50

At a glance

  • Originator Jiangsu Jindike Biotechnology
  • Developer Jiangsu Jindike Biotechnology; Jiangsu Provincial Center for Disease Control and Prevention
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Influenza virus infections

Most Recent Events

  • 01 Aug 2016 Jiangsu Province Centers for Disease Control and Prevention completes a phase III clinical trial in Influenza virus infections (Prevention, In volunteers, In adolescents, In children, In adults) in China (IM) (NCT02710409)
  • 01 Jan 2016 Phase-III clinical trials in Influenza virus infections (Prevention, In volunteers, In adolescents, In children, In adults) in China (IM) (NCT02710409)
  • 01 May 2015 Phase-I clinical trials in Influenza virus infections (Prevention) in China (Parenteral) (NCT02269007)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top